Mabwell (Shanghai) Bioscience Co., Ltd. Class A

As of June 30, 2026, Mabwell (Shanghai) Bioscience Co., Ltd. Class A carries a market capitalization of 12.62B, placing it among publicly traded companies globally. Its enterprise value stands at 13.81B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Mabwell (Shanghai) Bioscience Co., Ltd. Class A's next confirmed earnings release is scheduled for October 28, 2026.

As of June 30, 2026, Mabwell (Shanghai) Bioscience Co., Ltd. Class A has 446.73M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 24.62, and the price-to-book ratio stands at 14.45.

These figures are as of June 30, 2026. The EV/Sales ratio of 29.66 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 13.81B versus a market cap of 12.62B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Mabwell (Shanghai) Bioscience Co., Ltd. Class A maintains a current ratio of 1.25, meaning it holds 1.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 313.19, indicating elevated leverage, while an interest coverage ratio of -10.51 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Mabwell (Shanghai) Bioscience Co., Ltd. Class A posted a negative return on equity (ROE) of -107.22, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -24.31, reflecting losses generated across the asset base. The company generates approximately 345,535.84 in revenue per employee across its workforce of 1,347.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.55 indicates how many times Mabwell (Shanghai) Bioscience Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Mabwell (Shanghai) Bioscience Co., Ltd. Class A recorded an income tax benefit of -665,755.82 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -1.16B and -1.15B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Mabwell (Shanghai) Bioscience Co., Ltd. Class A's stock has declined approximately 51.20% over the past 52 weeks. The 50-day moving average sits at 27.51, while the 200-day moving average is 32.78.

Over the twelve months ended June 30, 2026, Mabwell (Shanghai) Bioscience Co., Ltd. Class A generated 465.70M in revenue and converted that into -1.15B in net income, yielding earnings per share of -2.85. EBITDA reached -1.15B, while operating income came in at -1.02B.

As of June 30, 2026, Mabwell (Shanghai) Bioscience Co., Ltd. Class A holds 2.29B in cash and equivalents against 3.30B in total debt, resulting in a net debt position of 644.82M. Total book value stands at 873.49M, with working capital of 572.92M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Mabwell (Shanghai) Bioscience Co., Ltd. Class A posted a gross margin of 75.53, reflecting its pricing power and cost economics. The operating margin of -218.52 and net profit margin of -247.58 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Mabwell (Shanghai) Bioscience Co., Ltd. Class A paid dividends of 0.21 per share. The dividend payout ratio of -7.32 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -14.45, meaning Mabwell (Shanghai) Bioscience Co., Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Mabwell (Shanghai) Bioscience Co., Ltd. Class A has an Altman Z-Score of -0.40, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.